- IRAK DEGRADERS AND USES THEREOF
-
The present invention provides compounds, compositions thereof, and methods of using the same.
- -
-
Paragraph 2499; 2500
(2019/07/10)
-
- FLT3 INHIBITORS AND USES THEREOF
-
The present invention provides methods of using compounds of formula I: or compositions thereof for the inhibition of FLT3, and the treatment of FLT3-mediated disorders.
- -
-
Paragraph 00271-00272
(2014/12/12)
-
- CDK8 INHIBITORS AND USES THEREOF
-
The present invention provides methods of using compounds of formula I: and compositions thereof for the inhibition of CDK8, and the treatment of CDK8-mediated disorders.
- -
-
Paragraph 00281
(2014/12/12)
-
- IRAK INHIBITORS AND USES THEREOF
-
The present invention provides thieno[2,3-d]pyrimidine derivative compounds, and pharmaceutical compositions thereof. The invention also includes methods inhibiting an IRAK protein kinase in a patient by administering the thieno[2,3-d]pyrimidine derivative compound. The invention also includes methods of treating an IRAK-mediated disorder, disease, or condition in a patient by administering the thieno[2,3-d]pyrimidine derivative compound.
- -
-
Paragraph 00366
(2013/07/25)
-
- IRAK INHIBITORS AND USES THEREOF
-
The present invention relates to compounds and methods useful for inhibiting one or more interleukin-l receptor-associated kinases ("IRAK"). In some embodiments, a provided compound inhibits IRAK-1 and IRAK-4. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
- -
-
Page/Page column 256-257
(2012/07/28)
-
- HETEROTRICYCLIC METALLOPROTEASE INHIBITORS
-
The present invention relates generally to azatricyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 a
- -
-
Page/Page column 76
(2008/12/05)
-